[시장보고서]세계의 임상 미생물학 시장 : 제품별, 질환 영역별, 최종사용자별, 지역별

세계의 임상 미생물학 시장 : 제품별, 질환 영역별, 최종사용자별, 지역별 - 예측(-2030년)

Clinical Microbiology Market by Product (Instrument, Analyzer, Reagent, Kits, Media), Disease Area, End User - Global Forecast to 2030

상품코드 : 1819089 해당 상품은 즉시 배송 가능합니다

리서치사 : MarketsandMarkets

발행일 : 2025년 09월

페이지 정보 : 영문 411 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,950

￦ 7,354,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650

￦ 9,879,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150

￦ 12,108,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000

￦ 14,857,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

임상 미생물학 시장 규모는 예측 기간 중에 6.6%의 연평균 복합 성장률(CAGR)로 확대되어 2030년까지 73억 4,000만 달러에 이를 것으로 예측됩니다.

조사 범위
조사 대상 연도	2024-2030년
기준 연도	2024년
예측 기간	2025-2030년
검토 단위	금액(10억 달러)
부문	제품별, 질환 영역별, 최종사용자별, 지역별
대상 지역	북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카

임상 미생물학 시장은 신속한 분자 검사, 실험실 자동화 등 감염 요인을 신속하고 정확하게 검출할 수 있는 진단 기술의 발전에 힘입어 강력한 성장세를 보이고 있습니다. 또한, 인구 증가, 도시화, 해외여행 증가로 인해 전 세계적으로 감염병에 대한 부담이 증가하고 있는 것도 첨단 미생물 검사 솔루션에 대한 수요를 더욱 가속화시키고 있습니다.

임상 미생물학 시장은 기기, 시약, 배지 및 혈청으로 구분됩니다. 장비 부문이 시장에서 가장 큰 점유율을 차지하고 있습니다. 이러한 우위는 유전체 연구에서의 산학협력 증가와 함께 연구자 및 학술 기관에서 기존 검사 장비를 광범위하게 채택하는 등 몇 가지 요인에 기인합니다. 또한, 마이크로유체공학과 PCR의 통합, qPCR에 나노기술의 적용 등 분자기술과 단백질체학의 발전이 성장을 가속하고 있습니다.

시장은 최종 사용자별로 병원 및 진단센터, 수탁검사기관, 학술 및 연구기관으로 구분됩니다. 2024년에는 병원 및 진단센터 시장이 가장 큰 시장 점유율을 차지했습니다. 이는 병원 설립 증가, 연구개발 활동의 진단센터 아웃소싱 증가, 만성질환 부담 증가, 병원의 첨단 의료 인프라에 대한 투자 능력에 기인합니다.

세계 임상 미생물학 시장은 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 구분됩니다. 아시아태평양은 예측 기간 동안 가장 높은 성장률을 나타낼 것으로 예측됩니다. 이 지역의 신흥국들은 GDP가 안정적으로 성장하고 가처분 소득이 눈에 띄게 증가함에 따라 광범위한 인구층에서 의료비 지출이 증가하고 있습니다. 기타 성장 촉진요인으로는 감염성 질환의 발병률과 유병률 증가, 의료 인프라의 현대화, 특히 농촌 지역의 첨단 진단 기술 채택 확대 등을 들 수 있습니다. 이러한 요인들은 아시아태평양의 임상 미생물학 관련 기업들에게 큰 성장 기회를 제공할 것으로 예측됩니다.

세계의 임상 미생물학 시장에 대해 조사했으며, 제품별, 질병 영역별, 최종사용자별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 정리하여 전해드립니다.

서론
시장 역학
가격 분석
특허 분석
밸류체인 분석
공급망 분석
무역 분석
생태계 분석
Porter의 Five Forces 분석
규제 상황
기술 분석
2025-2026년 주요 컨퍼런스 및 이벤트
고객의 비즈니스에 영향을 미치는 동향/파괴적 변화
주요 이해관계자와 구입 기준
투자 및 자금조달 시나리오
사례 연구 분석
임상 미생물학 시장 AI/생성형 AI의 영향
임상 미생물학 시장에 대한 트럼프 관세의 영향

제6장 임상 미생물학 시장(제품별)

서론
기기
시약
배지 및 혈청

제7장 임상 미생물학 시장(질환 영역별)

서론
호흡기질환
혈류감염
소화기 질환
성감염증
요로감염
치주질환
기타

제8장 임상 미생물학 시장(최종사용자별)

서론
병원 및 진단센터
수탁연구기관
학술연구기관

제9장 임상 미생물학 시장(지역별)

서론
북미
- 북미 : 거시경제 전망
- 미국
- 캐나다
유럽
- 유럽 : 거시경제 전망
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 기타
아시아태평양
- 아시아태평양 : 거시경제 전망
- 중국
- 일본
- 인도
- 한국
- 호주
- 기타
라틴아메리카
- 라틴아메리카 : 거시경제 전망
- 브라질
- 멕시코
- 기타
중동 및 아프리카
- 중동 및 아프리카 : 거시경제 전망
- 사우디아라비아(KSA)
- 아랍에미리트(UAE)
- 기타

제10장 경쟁 구도

서론
주요 시장 진출기업의 전략과 강점
매출 분배 분석
시장 점유율 분석, 2024년
기업 평가 매트릭스 : 주요 시장 진출기업, 2024년
기업 평가 매트릭스 : 스타트업/중소기업, 2024년
기업 평가와 재무 지표
브랜드 및 제품 비교
경쟁 시나리오

제11장 기업 개요

주요 시장 진출기업
- BIOMERIEUX
- DANAHER CORPORATION
- BECTON, DICKINSON AND COMPANY(BD)
- THERMO FISHER SCIENTIFIC INC.
- F. HOFFMANN-LA ROCHE LTD.
- ABBOTT LABORATORIES
- AGILENT TECHNOLOGIES, INC.
- BRUKER CORPORATION
- HOLOGIC, INC.
- MERCK KGAA
- BIO-RAD LABORATORIES, INC.
- QIAGEN
- SIEMENS HEALTHINEERS AG
기타 기업
- SHIMADZU CORPORATION
- NEOGEN CORPORATION
- SEEGENE INC.
- RAPID MICRO BIOSYSTEMS, INC.
- HARDY DIAGNOSTICS
- EMSL ANALYTICAL, INC.
- LIOFILCHEM S.R.L.
- TCS BIOSCIENCES LTD.
- MEMMERT GMBH+CO.KG
- VACUTEST KIMA S.R.L
- CREATIVE DIAGNOSTICS
- DCN DX

제12장 부록

LSH

영문 목차

영문목차

The clinical microbiology market is projected to reach USD 7.34 billion by 2030, growing at a CAGR of 6.6% during the forecast period.

Scope of the Report
Years Considered for the Study	2024-2030
Base Year	2024
Forecast Period	2025-2030
Units Considered	Value (USD billion)
Segments	Product, Disease Area, and End User
Regions covered	North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa

The clinical microbiology market is witnessing strong growth, driven by advancements in diagnostic technologies such as rapid molecular testing and laboratory automation, which enable faster & accurate detection of infectious agents. In addition, the rising global burden of infectious diseases, fueled by population growth, urbanization, and increased international travel, further accelerates the demand for advanced microbiology testing solutions.

By product, the instruments segment accounted for the largest market share in 2024.

The clinical microbiology market is segmented into instruments, reagents, and media & sera. The instruments segment accounted for the largest share of the market. This dominance is driven by several factors, including the widespread adoption of conventional laboratory instruments by researchers & academic institutions, alongside increasing industry-academia collaborations in genomic research. Additionally, molecular techniques and proteomics advancements, such as integrating microfluidics with PCR and applying nanotechnology to qPCR, are fuelling the growth.

By end user, the hospitals & diagnostic centers segment accounted for the largest share of the market in 2024.

The market is segmented by end user into hospitals & diagnostic centers, contract testing laboratories, and academic & research institutes. In 2024, the hospitals & diagnostic laboratories segment accounted for the largest market share owing to the rising establishment of hospitals, the increasing outsourcing of R&D activities to diagnostic laboratories, the increasing burden of chronic diseases, and the ability of hospitals to invest in advanced healthcare infrastructure.

Asia Pacific is projected to grow at the highest CAGR during the forecast period.

The global clinical microbiology market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest growth rate during the forecast period. Emerging economies in this region are seeing consistent GDP growth and a notable rise in disposable income, contributing to increased healthcare spending across a broader population base. Additional growth drivers include the rising incidence and prevalence of infectious diseases, the modernization of healthcare infrastructure, and the growing adoption of advanced diagnostic technologies, particularly in rural areas. These factors are anticipated to create substantial growth opportunities for clinical microbiology companies in the Asia Pacific.

The break-up of the profile of primary participants in the clinical microbiology market:

By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
By Designation: C-level - 27%, D-level - 18%, and Others - 55%
By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and the Middle East & Africa- 4%

The key players in this market are bioMerieux (France), Danaher Corporation (US), Becton, Dickinson and Company (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott (US), Agilent Technologies, Inc. (US), Bruker Corporation (US), Hologic, Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), QIAGEN (Netherlands), Siemens Healthineers AG (Germany), Shimadzu Corporation (Japan), and Neogen Corporation (US), among others.

Research Coverage:

This research report categorizes the clinical microbiology market by product (instruments, reagents, and media & sera), by disease area (respiratory diseases, bloodstream infections, gastrointestinal diseases, sexually transmitted diseases, urinary tract infections, periodontal diseases, and other diseases), by end user (hospitals & diagnostic centers, contract testing laboratories, and academic & research institutes), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa).

Reasons To Buy This Report:

The report will help the market leaders/new entrants with information on the closest approximations of the revenue numbers for the overall clinical microbiology market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

Analysis of key drivers (technological advancements in clinical diagnosis and novel molecular diagnostic-based instruments, rising incidence of infectious diseases and epidemics, increasing R&D programs and public-private investments), opportunities (improved healthcare infrastructure in emerging countries), restraints (limited reimbursement policies for clinical microbiology testing procedures), and challenges (operational barriers to diagnostic microbiology tests in emerging countries) influencing the growth of the clinical microbiology market.
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the clinical microbiology market.
Market Development: Comprehensive information about lucrative markets - the report analyses the clinical microbiology market across varied regions.
Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the clinical microbiology market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like bioMerieux (France), Danaher Corporation (US), Becton, Dickinson and Company (US), Thermo Fisher Scientific Inc. (US), and F. Hoffmann-La Roche Ltd. (Switzerland), among others, in the clinical microbiology market.

1 INTRODUCTION

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
- 1.3.1 MARKETS & REGIONS COVERED
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
1.4 KEY STAKEHOLDERS
1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
- 2.2.1 SECONDARY DATA
  - 2.2.1.1 Key secondary sources
  - 2.2.1.2 Key data from secondary sources
- 2.2.2 PRIMARY DATA
  - 2.2.2.1 Primary sources
  - 2.2.2.2 Key data from primary sources
  - 2.2.2.3 Key industry insights
  - 2.2.2.4 Breakdown of primary interviews
2.3 MARKET SIZE ESTIMATION
- 2.3.1 BOTTOM-UP APPROACH
  - 2.3.1.1 Approach 1: Company revenue estimation approach
  - 2.3.1.2 Approach 2: Presentations of companies and primary interviews
  - 2.3.1.3 Growth forecast
  - 2.3.1.4 CAGR projections
- 2.3.2 TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
2.5 MARKET SHARE ASSESSMENT
2.6 RESEARCH ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 CLINICAL MICROBIOLOGY MARKET OVERVIEW
4.2 CLINICAL MICROBIOLOGY MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)
4.3 CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA, 2025 VS. 2030 (USD MILLION)
4.4 CLINICAL MICROBIOLOGY MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
4.5 CLINICAL MICROBIOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
  - 5.2.1.1 Technological advancements and development of novel molecular diagnostic-based instruments
  - 5.2.1.2 Rising incidence of infectious diseases and epidemics
  - 5.2.1.3 Increasing focus on R&D programs and public-private investments
- 5.2.2 RESTRAINTS
  - 5.2.2.1 Limited reimbursement policies for clinical microbiology testing procedures
- 5.2.3 OPPORTUNITIES
  - 5.2.3.1 Improved healthcare infrastructure in emerging economies
- 5.2.4 CHALLENGES
  - 5.2.4.1 Operational barriers for diagnostic microbiology tests
5.3 PRICING ANALYSIS
- 5.3.1 AVERAGE SELLING PRICE TREND OF CLINICAL MICROBIOLOGY PRODUCTS
- 5.3.2 AVERAGE SELLING PRICE TREND OF CLINICAL MICROBIOLOGY TEST KITS, BY KEY PLAYER, 2023-2025
- 5.3.3 AVERAGE SELLING PRICE TREND OF CLINICAL MICROBIOLOGY PRODUCTS, BY REGION, 2023-2025
5.4 PATENT ANALYSIS
- 5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 TRADE ANALYSIS
- 5.7.1 TRADE ANALYSIS FOR OPTICAL MICROSCOPES
- 5.7.2 IMPORT DATA (HS CODE 9011)
- 5.7.3 EXPORT DATA (HS CODE 9011)
5.8 ECOSYSTEM ANALYSIS
- 5.8.1 CLINICAL MICROBIOLOGY MARKET: ROLE IN ECOSYSTEM
5.9 PORTER'S FIVE FORCES ANALYSIS
- 5.9.1 THREAT OF NEW ENTRANTS
- 5.9.2 THREAT OF SUBSTITUTES
- 5.9.3 BARGAINING POWER OF BUYERS
- 5.9.4 BARGAINING POWER OF SUPPLIERS
- 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 REGULATORY LANDSCAPE
- 5.10.1 REGULATORY FRAMEWORK
  - 5.10.1.1 North America
    - 5.10.1.1.1 US
    - 5.10.1.1.2 Canada
  - 5.10.1.2 Europe
    - 5.10.1.2.1 Germany
    - 5.10.1.2.2 UK
    - 5.10.1.2.3 France
    - 5.10.1.2.4 Italy
  - 5.10.1.3 Asia Pacific
    - 5.10.1.3.1 China
    - 5.10.1.3.2 Japan
    - 5.10.1.3.3 India
  - 5.10.1.4 Latin America
    - 5.10.1.4.1 Brazil
    - 5.10.1.4.2 Mexico
  - 5.10.1.5 Middle East
    - 5.10.1.5.1 Africa
- 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11 TECHNOLOGY ANALYSIS
- 5.11.1 KEY TECHNOLOGIES
  - 5.11.1.1 MALDI-TOF mass spectrometry
- 5.11.2 COMPLEMENTARY TECHNOLOGIES
  - 5.11.2.1 Optical immunosensors
  - 5.11.2.2 Electrochemical immunosensors
- 5.11.3 ADJACENT TECHNOLOGIES
  - 5.11.3.1 Automated multiplex PCR systems
5.12 KEY CONFERENCES & EVENTS, 2025-2026
5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
5.14 KEY STAKEHOLDERS & BUYING CRITERIA
- 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.14.2 BUYING CRITERIA
5.15 INVESTMENT & FUNDING SCENARIO
5.16 CASE STUDY ANALYSIS
- 5.16.1 CASE STUDY 1: IMPACT OF MALDI-TOF MS AND RAPID SUSCEPTIBILITY TESTING ON SEPSIS MANAGEMENT
- 5.16.2 CASE STUDY 2: IMPACT OF MULTIPLEX PCR PANELS IN MANAGING ACUTE GASTROENTERITIS IN ED
5.17 IMPACT OF AI/GENERATIVE AI IN CLINICAL MICROBIOLOGY MARKET
- 5.17.1 INTRODUCTION
- 5.17.2 MARKET POTENTIAL OF AI
- 5.17.3 AI-USE CASES
- 5.17.4 IMPLEMENTATION OF AI, BY KEY COMPANY & CASE
- 5.17.5 FUTURE OF AI IN CLINICAL MICROBIOLOGY MARKET
5.18 TRUMP TARIFF IMPACT ON CLINICAL MICROBIOLOGY MARKET
- 5.18.1 INTRODUCTION
- 5.18.2 KEY TARIFF RATES
- 5.18.3 PRICE IMPACT ANALYSIS
- 5.18.4 KEY IMPACT ON COUNTRY/REGION
  - 5.18.4.1 North America
  - 5.18.4.2 Europe
  - 5.18.4.3 Asia Pacific
- 5.18.5 IMPACT ON END-USE INDUSTRIES
  - 5.18.5.1 Hospitals & diagnostic centers
  - 5.18.5.2 Contract testing laboratories
  - 5.18.5.3 Academic & research institutes

6 CLINICAL MICROBIOLOGY MARKET, BY PRODUCT

6.1 INTRODUCTION
6.2 INSTRUMENTS
- 6.2.1 LABORATORY INSTRUMENTS
  - 6.2.1.1 Incubators
    - 6.2.1.1.1 Rising demand for cell culture applications to drive market
  - 6.2.1.2 Gram stainers
    - 6.2.1.2.1 Rapid, accurate screening of bacterial pathogens to fuel uptake
  - 6.2.1.3 Bacterial colony counters
    - 6.2.1.3.1 Increased focus on accurate bacterial quantification to drive market
  - 6.2.1.4 Autoclave sterilizers
    - 6.2.1.4.1 Increasing focus on infection control in healthcare facilities to support market growth
  - 6.2.1.5 Microbial air samplers
    - 6.2.1.5.1 Need for enhanced air quality monitoring in cleanrooms to accelerate segment growth
  - 6.2.1.6 Anaerobic culture systems
    - 6.2.1.6.1 Increased research on anaerobic microorganisms to boost segment growth
  - 6.2.1.7 Petri dish fillers
    - 6.2.1.7.1 Need for minimal bench space and effective control with graphical user interfaces to aid segment growth
  - 6.2.1.8 Blood culture systems
    - 6.2.1.8.1 Technological advancements in diagnostic testing to drive market
  - 6.2.1.9 Microbial culture systems
    - 6.2.1.9.1 Increase in biopharmaceutical research to augment segment growth
  - 6.2.1.10 Other laboratory instruments
- 6.2.2 MICROBIOLOGY ANALYZERS
  - 6.2.2.1 Molecular diagnostic instruments
    - 6.2.2.1.1 Advancements in multiplexing techniques and high adoption of genomics-based analysis to aid market growth
  - 6.2.2.2 Microscopes
    - 6.2.2.2.1 Rising demand for high-resolution imaging to propel market
  - 6.2.2.3 Mass spectrometers
    - 6.2.2.3.1 Increased applications in proteomics & metabolomics to boost market
6.3 REAGENTS
- 6.3.1 PATHOGEN-SPECIFIC KITS
  - 6.3.1.1 Increasing private-public initiatives for research to support market growth
- 6.3.2 GENERAL REAGENTS
  - 6.3.2.1 Rising demand for diagnostic tests for pathogen detection to propel segment growth
6.4 MEDIA & SERA
- 6.4.1 RISING DEMAND FOR STANDARDIZED CULTURE MEDIA FOR MICROBIOLOGICAL TESTING TO PROPEL MARKET

7 CLINICAL MICROBIOLOGY MARKET, BY DISEASE AREA

7.1 INTRODUCTION
7.2 RESPIRATORY DISEASES
- 7.2.1 EXPANSION OF RESPIRATORY DISEASE SURVEILLANCE PROGRAMS TO DRIVE MARKET
7.3 BLOODSTREAM INFECTIONS
- 7.3.1 GROWING INCIDENCE OF HOSPITAL-ACQUIRED INFECTIONS TO DRIVE MARKET
7.4 GASTROINTESTINAL DISEASES
- 7.4.1 HIGH RISK OF FOOD- AND WATER-BORNE INFECTIONS TO AID MARKET
7.5 SEXUALLY TRANSMITTED DISEASES
- 7.5.1 INCREASING EMPHASIS ON EARLY & EFFECTIVE DISEASE DIAGNOSIS TO BOOST DEMAND
7.6 URINARY TRACT INFECTIONS
- 7.6.1 FOCUS ON PREVENTIVE CARE TO SUPPORT MARKET GROWTH
7.7 PERIODONTAL DISEASES
- 7.7.1 INCREASING R&D INITIATIVES TO STUDY MICROBE-INDUCED DISEASES TO FUEL MARKET
7.8 OTHER DISEASES

8 CLINICAL MICROBIOLOGY MARKET, BY END USER

8.1 INTRODUCTION
8.2 HOSPITALS & DIAGNOSTIC CENTERS
- 8.2.1 INCREASING PATIENT VOLUME AND RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET
8.3 CONTRACT TESTING LABORATORIES
- 8.3.1 LOW-COST OUTSOURCING OF TESTING ACTIVITIES TO LABORATORIES TO PROPEL MARKET
8.4 ACADEMIC & RESEARCH INSTITUTES
- 8.4.1 EXPANSION OF RESEARCH INITIATIVES AND FAVORABLE FUNDING INVESTMENTS TO BOOST MARKET

9 CLINICAL MICROBIOLOGY MARKET, BY REGION

9.1 INTRODUCTION
9.2 NORTH AMERICA
- 9.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
- 9.2.2 US
  - 9.2.2.1 Increasing prevalence of infectious diseases to drive market
- 9.2.3 CANADA
  - 9.2.3.1 Supportive government initiatives and increased research funding to boost market
9.3 EUROPE
- 9.3.1 EUROPE: MACROECONOMIC OUTLOOK
- 9.3.2 GERMANY
  - 9.3.2.1 Favorable government policies to propel market
- 9.3.3 FRANCE
  - 9.3.3.1 Favorable healthcare reforms and investments in diagnostic infrastructure to drive market
- 9.3.4 UK
  - 9.3.4.1 Rising acceptance of genome-based diagnostic techniques to fuel market
- 9.3.5 ITALY
  - 9.3.5.1 Improved healthcare services and better disease surveillance to support market growth
- 9.3.6 SPAIN
  - 9.3.6.1 Growing focus on public healthcare initiatives to augment market growth
- 9.3.7 REST OF EUROPE
9.4 ASIA PACIFIC
- 9.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
- 9.4.2 CHINA
  - 9.4.2.1 Increasing government focus on disease prevention to drive market
- 9.4.3 JAPAN
  - 9.4.3.1 Technological advancements in diagnostic kits to fuel uptake
- 9.4.4 INDIA
  - 9.4.4.1 High target patient population to boost demand
- 9.4.5 SOUTH KOREA
  - 9.4.5.1 Favorable government initiatives for medical tourism to support market growth
- 9.4.6 AUSTRALIA
  - 9.4.6.1 Favorable healthcare automation techniques to support market growth
- 9.4.7 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
- 9.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
- 9.5.2 BRAZIL
  - 9.5.2.1 Universal healthcare access to drive market
- 9.5.3 MEXICO
  - 9.5.3.1 Increasing prevalence of HIV to drive market
- 9.5.4 REST OF LATIN AMERICA
9.6 MIDDLE EAST & AFRICA
- 9.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
- 9.6.2 KINGDOM OF SAUDI ARABIA (KSA)
  - 9.6.2.1 Increasing focus on healthcare automation to drive market
- 9.6.3 UNITED ARAB EMIRATES (UAE)
  - 9.6.3.1 Improvements in healthcare infrastructure to support market growth
- 9.6.4 REST OF MIDDLE EAST & AFRICA

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 10.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN CLINICAL MICROBIOLOGY MARKET
10.3 REVENUE SHARE ANALYSIS
10.4 MARKET SHARE ANALYSIS, 2024
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
- 10.5.1 STARS
- 10.5.2 EMERGING LEADERS
- 10.5.3 PERVASIVE PLAYERS
- 10.5.4 PARTICIPANTS
- 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
  - 10.5.5.1 Company footprint
  - 10.5.5.2 Region footprint
  - 10.5.5.3 Product footprint
  - 10.5.5.4 Instruments footprint
  - 10.5.5.5 Disease area footprint
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
- 10.6.1 PROGRESSIVE COMPANIES
- 10.6.2 RESPONSIVE COMPANIES
- 10.6.3 DYNAMIC COMPANIES
- 10.6.4 STARTING BLOCKS
- 10.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  - 10.6.5.1 Detailed list of key startups/SMEs
  - 10.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
  - 10.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
10.7 COMPANY VALUATION & FINANCIAL METRICS
- 10.7.1 FINANCIAL METRICS
- 10.7.2 COMPANY VALUATION
10.8 BRAND/PRODUCT COMPARISON
- 10.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS
10.9 COMPETITIVE SCENARIO
- 10.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
- 10.9.2 DEALS
- 10.9.3 EXPANSIONS

11 COMPANY PROFILES

11.1 KEY PLAYERS
- 11.1.1 BIOMERIEUX
  - 11.1.1.1 Business overview
  - 11.1.1.2 Products/Services offered
  - 11.1.1.3 Recent developments
    - 11.1.1.3.1 Product/Service launches & approvals
    - 11.1.1.3.2 Deals
  - 11.1.1.4 MnM view
    - 11.1.1.4.1 Key strengths
    - 11.1.1.4.2 Strategic choices
    - 11.1.1.4.3 Weaknesses & competitive threats
- 11.1.2 DANAHER CORPORATION
  - 11.1.2.1 Business overview
  - 11.1.2.2 Products/Services offered
  - 11.1.2.3 Recent developments
    - 11.1.2.3.1 Product/Service launches & approvals
    - 11.1.2.3.2 Deals
    - 11.1.2.3.3 Expansions
  - 11.1.2.4 MnM view
    - 11.1.2.4.1 Key strengths
    - 11.1.2.4.2 Strategic choices
    - 11.1.2.4.3 Weaknesses & competitive threats
- 11.1.3 BECTON, DICKINSON AND COMPANY (BD)
  - 11.1.3.1 Business overview
  - 11.1.3.2 Products/Services offered
  - 11.1.3.3 Recent developments
    - 11.1.3.3.1 Product/Service launches & approvals
    - 11.1.3.3.2 Deals
    - 11.1.3.3.3 Expansions
  - 11.1.3.4 MnM view
    - 11.1.3.4.1 Key strengths
    - 11.1.3.4.2 Strategic choices
    - 11.1.3.4.3 Weaknesses & competitive threats
- 11.1.4 THERMO FISHER SCIENTIFIC INC.
  - 11.1.4.1 Business overview
  - 11.1.4.2 Products/Services offered
  - 11.1.4.3 Recent developments
    - 11.1.4.3.1 Product/Service launches & approvals
    - 11.1.4.3.2 Deals
  - 11.1.4.4 MnM view
    - 11.1.4.4.1 Key strengths
    - 11.1.4.4.2 Strategic choices
    - 11.1.4.4.3 Weaknesses & competitive threats
- 11.1.5 F. HOFFMANN-LA ROCHE LTD.
  - 11.1.5.1 Business overview
  - 11.1.5.2 Products/Services offered
  - 11.1.5.3 Recent developments
    - 11.1.5.3.1 Product/Service launches & approvals
    - 11.1.5.3.2 Deals
    - 11.1.5.3.3 Expansions
  - 11.1.5.4 MnM view
    - 11.1.5.4.1 Key strengths
    - 11.1.5.4.2 Strategic choices
    - 11.1.5.4.3 Weaknesses & competitive threats
- 11.1.6 ABBOTT LABORATORIES
  - 11.1.6.1 Business overview
  - 11.1.6.2 Products/Services offered
  - 11.1.6.3 Recent developments
    - 11.1.6.3.1 Deals
- 11.1.7 AGILENT TECHNOLOGIES, INC.
  - 11.1.7.1 Business overview
  - 11.1.7.2 Products/Services offered
  - 11.1.7.3 Recent developments
    - 11.1.7.3.1 Expansions
- 11.1.8 BRUKER CORPORATION
  - 11.1.8.1 Business overview
  - 11.1.8.2 Products/Services offered
  - 11.1.8.3 Recent developments
    - 11.1.8.3.1 Product/Service launches & approvals
    - 11.1.8.3.2 Deals
- 11.1.9 HOLOGIC, INC.
  - 11.1.9.1 Business overview
  - 11.1.9.2 Products/Services offered
  - 11.1.9.3 Recent developments
    - 11.1.9.3.1 Product/Service launches & approvals
    - 11.1.9.3.2 Deals
- 11.1.10 MERCK KGAA
  - 11.1.10.1 Business overview
  - 11.1.10.2 Products/Services offered
  - 11.1.10.3 Recent developments
    - 11.1.10.3.1 Deals
    - 11.1.10.3.2 Expansions
- 11.1.11 BIO-RAD LABORATORIES, INC.
  - 11.1.11.1 Business overview
  - 11.1.11.2 Products/Services offered
  - 11.1.11.3 Recent developments
    - 11.1.11.3.1 Deals
- 11.1.12 QIAGEN
  - 11.1.12.1 Business overview
  - 11.1.12.2 Products/Services offered
  - 11.1.12.3 Recent developments
    - 11.1.12.3.1 Product/Service launches
    - 11.1.12.3.2 Deals
    - 11.1.12.3.3 Expansions
- 11.1.13 SIEMENS HEALTHINEERS AG
  - 11.1.13.1 Business overview
  - 11.1.13.2 Products/Services offered
  - 11.1.13.3 Recent developments
    - 11.1.13.3.1 Product/Service launches
    - 11.1.13.3.2 Deals
    - 11.1.13.3.3 Expansions
11.2 OTHER PLAYERS
- 11.2.1 SHIMADZU CORPORATION
- 11.2.2 NEOGEN CORPORATION
- 11.2.3 SEEGENE INC.
- 11.2.4 RAPID MICRO BIOSYSTEMS, INC.
- 11.2.5 HARDY DIAGNOSTICS
- 11.2.6 EMSL ANALYTICAL, INC.
- 11.2.7 LIOFILCHEM S.R.L.
- 11.2.8 TCS BIOSCIENCES LTD.
- 11.2.9 MEMMERT GMBH + CO.KG
- 11.2.10 VACUTEST KIMA S.R.L
- 11.2.11 CREATIVE DIAGNOSTICS
- 11.2.12 DCN DX

12 APPENDIX

12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS